MTCO1P20

Across TCGA pan-cancer cohorts, MTCO1P20 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of MTCO1P20’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where MTCO1P20 RNA is repressed in tumor relative to normal tissue. In most cancer types MTCO1P20 is over-expressed in tumor, although a few such as BRCA and LUSC show the opposite, repressed pattern.

BRCA, LUSC, and KIRC are the cancer types where MTCO1P20 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MTCO1P20 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	All	−0.077	.001	4	view →
LUSC	Male	II,III,IV	−0.126	.047	1	view →
KIRC	Female	All	+0.083	.031	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

MTCO1P20–BRCA

Open the BRCA breakdown →